Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability

Viral mutations are an emerging concern in reducing SARS-CoV-2 vaccination efficacy. Second-generation vaccines will need to elicit neutralizing antibodies against sites that are evolutionarily conserved across the sarbecovirus subgenus. Here, we immunized mice containing a human antibody repertoire...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Immunity (Cambridge, Mass.) Mass.), 2021-12, Vol.54 (12), p.2908-2921.e6
Hauptverfasser: Burnett, Deborah L., Jackson, Katherine J.L., Langley, David B., Aggarwal, Anupriya, Stella, Alberto Ospina, Johansen, Matt D., Balachandran, Harikrishnan, Lenthall, Helen, Rouet, Romain, Walker, Gregory, Saunders, Bernadette M., Singh, Mandeep, Li, Hui, Henry, Jake Y., Jackson, Jennifer, Stewart, Alastair G., Witthauer, Franka, Spence, Matthew A., Hansbro, Nicole G., Jackson, Colin, Schofield, Peter, Milthorpe, Claire, Martinello, Marianne, Schulz, Sebastian R., Roth, Edith, Kelleher, Anthony, Emery, Sean, Britton, Warwick J., Rawlinson, William D., Karl, Rudolfo, Schäfer, Simon, Winkler, Thomas H., Brink, Robert, Bull, Rowena A., Hansbro, Philip M., Jäck, Hans-Martin, Turville, Stuart, Christ, Daniel, Goodnow, Christopher C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Viral mutations are an emerging concern in reducing SARS-CoV-2 vaccination efficacy. Second-generation vaccines will need to elicit neutralizing antibodies against sites that are evolutionarily conserved across the sarbecovirus subgenus. Here, we immunized mice containing a human antibody repertoire with diverse sarbecovirus receptor-binding domains (RBDs) to identify antibodies targeting conserved sites of vulnerability. Antibodies with broad reactivity against diverse clade B RBDs targeting the conserved class 4 epitope, with recurring IGHV/IGKV pairs, were readily elicited but were non-neutralizing. However, rare class 4 antibodies binding this conserved RBD supersite showed potent neutralization of SARS-CoV-2 and all variants of concern. Structural analysis revealed that the neutralizing ability of cross-reactive antibodies was reserved only for those with an elongated CDRH3 that extends the antiparallel beta-sheet RBD core and orients the antibody light chain to obstruct ACE2-RBD interactions. These results identify a structurally defined pathway for vaccine strategies eliciting escape-resistant SARS-CoV-2 neutralizing antibodies. [Display omitted] •Immunization with diverse sarbecorvirus RBDs induces cross-reactive antibodies•Cross-reactive antibodies use recurrent IGHV/IGKVs that mainly bind the class 4 epitope•Diverse sarbecovirus RBD responses vary in the dominance of class 4 epitope antibodies•Neutralizing class 4 antibodies are rare and extend the RBD beta-sheet main chain Viral mutations are an emerging concern in reducing SARS-CoV-2 vaccination efficacy. Burnett et al. immunized humanized mice with different diverse sarbecovirus RBDs to elicit antibodies targeting conserved sites. Non-neutralizing cross-reactive antibodies targeting the conserved class 4 epitope were readily elicited. Neutralizing ability was reserved only for antibodies binding this conserved supersite through an elongated CDRH3 that obstructed ACE2-RBD interactions.
ISSN:1074-7613
1097-4180
DOI:10.1016/j.immuni.2021.10.019